SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:umu-9358"
 

Sökning: id:"swepub:oai:DiVA.org:umu-9358" > Endometrial safety ...

Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy

Ödmark, Inga-Stina, 1948- (författare)
Umeå universitet,Obstetrik och gynekologi
Bixo, Marie (författare)
Umeå universitet,Obstetrik och gynekologi
Englund, Doris (författare)
visa fler...
Risberg, Björn (författare)
Jonsson, Björn (författare)
Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnendokrinologisk forskning/Tuvemo
Olsson, Sven-Eric (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
Ovid Technologies (Wolters Kluwer Health), 2005
2005
Engelska.
Ingår i: Menopause. - : Ovid Technologies (Wolters Kluwer Health). - 1072-3714 .- 1530-0374. ; 12:6, s. 699-707
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective: To determine compliance, the incidence of untoward effects, and endometrial safety in postmenopausal women treated with 3-month sequential hormone therapy for up to 5 years. Design: A prospective, uncontrolled multicenter study of 129 women treated with 0.625 mg conjugated estrogens daily plus 10 mg medroxyprogesterone acetate for 14 days every third month. Endometrial biopsy samples were taken before the initiation of the study and then yearly during the next 5 years. Bleeding patterns were recorded. Results: Upon completion of the first 12 months of treatment, 76 of 126 biopsied women (60%) had secretory endometrium. After 5 years, this finding was reversed in biopsy specimens completed by 59 women, among whom 32 (56%) had insufficient or atrophic endometrium.We did not find any hyperplasia when the biopsy specimen was taken according to the protocol. One endometrial cancer was found by biopsy after 12 months, but the subsequent hysterectomy showed no sign of cancer. Ultrasound determinations of mean endometrial thickness during therapy showed a thin endometrium (mean = 4 mm, range = 1-13 mm). Amenorrhea was reported by 6.2% of 129 women after 12 months of treatment. Among the 59 women who completed the study, 71.2% had regular bleeding patterns every third month, 25.4% reported amenorrhea, and 3.4% had irregular bleeding patterns. Conclusions: The addition of 10 mg of medroxyprogesterone acetate for 14 days every third month to treatment with 0.625 mg of conjugated estrogens daily was well tolerated, and was associated with high endometrial safety.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)

Nyckelord

Biopsy
Blood Pressure
Body Mass Index
Endometrium/*drug effects/pathology/ultrasonography
Estrogen Replacement Therapy/*methods
Estrogens; Conjugated (USP)/administration & dosage/*therapeutic use
Female
Humans
Medroxyprogesterone 17-Acetate/administration & dosage/*therapeutic use
Multivariate Analysis
Patient Dropouts/statistics & numerical data
Postmenopause
Prospective Studies
Uterine Hemorrhage/chemically induced/physiopathology
Obstetrics and gynaecology
Obstetrik och gynekologi
obstetrik och gynekologi
Obstetrics and Gynaecology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Menopause (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy